Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_4
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Completed1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed133%
not_yet_recruiting133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_4

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

NCT07245732
not_yet_recruitingphase_1

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07159906
completedphase_2

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

NCT03895801

Clinical Trials (3)

Showing 3 of 3 trials
NCT07245732Phase 4

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

Recruiting
NCT07159906Phase 1

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not Yet Recruiting
NCT03895801Phase 2

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3